China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging focused controlling subsidiary and Genoval Therapeutics Co., Ltd, a Shanghai-based developer of RNAi therapeutics. The collaboration aims to advance the development of multiple pioneering small nucleic acid drugs targeting the liver and extrahepatic tissues, addressing a range of diseases.
Scope of the Partnership
The partnership will focus on leveraging the expertise of both companies to develop innovative small nucleic acid drugs. These drugs have the potential to treat various conditions by targeting specific genetic pathways, offering new therapeutic options for patients.
Financial Details
The financial terms of the partnership have not been disclosed, indicating a focus on the collaborative development efforts and the potential scientific breakthroughs that could arise from this alliance.-Fineline Info & Tech
